Sign In
Buy VERX
$12.98
+0.600 (+4.85%)
At Close: Jul 13, 2026
New Pain Drug Could Be Big For Vertex Stock As Shares Score Breakout
04:28pm, Friday, 24'th May 2024
Cystic fibrosis treatment leader Vertex scored a breakout from a cup base this week, just a few weeks after an earnings beat.
Vertex to Participate in Upcoming June Investor Conferences
04:05pm, Wednesday, 22'nd May 2024
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Dr. Reshma Kewalramani, Chief Executive Offic
Vertex Women Leading the Way: Four Honorees Named on CRN's 2024 Women of the Channel List
11:30am, Monday, 13'th May 2024
KING OF PRUSSIA, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, today announced that CRN ® , a
Vertex, Inc. (VERX) Q1 2024 Earnings Call Transcript
01:33pm, Wednesday, 08'th May 2024
Vertex, Inc. (NASDAQ:VERX ) Q1 2024 Earnings Conference Call May 8, 2024 8:30 AM ET Company Participants Joe Crivelli – Vice President-Investor Relations David DeStefano – President and Chief Exec
Vertex Announces First Quarter 2024 Financial Results
07:02am, Wednesday, 08'th May 2024
KING OF PRUSSIA, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial r
Vertex, Inc. Announces Closing of Upsized Offering of $345 Million Convertible Senior Notes
05:09pm, Friday, 26'th Apr 2024
KING OF PRUSSIA, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex”), a leading global provider of indirect tax solutions, today announced the closing of its private off
Vertex, Inc. Announces Pricing of Upsized $300 Million
11:31pm, Tuesday, 23'rd Apr 2024
KING OF PRUSSIA, Pa., April 23, 2024 (GLOBE NEWSWIRE) — Vertex, Inc. (NASDAQ: VERX) (“Vertex”), a leading global provider of indirect tax solutions, today announced the pricing of $300 million a
Vertex, Inc. Announces Pricing of Upsized $300 Million Convertible Senior Notes Offering
09:53pm, Tuesday, 23'rd Apr 2024
KING OF PRUSSIA, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex”), a leading global provider of indirect tax solutions, today announced the pricing of $300 million ag
Vertex, Inc. Announces Proposed Private Offering of $250
08:02pm, Monday, 22'nd Apr 2024
KING OF PRUSSIA, Pa., April 22, 2024 (GLOBE NEWSWIRE) — Vertex, Inc. (NASDAQ: VERX) (“Vertex”), a leading global provider of indirect tax solutions, today announced that it intends to offer and
Vertex, Inc. Announces Proposed Private Offering of $250 Million of Convertible Senior Notes
04:17pm, Monday, 22'nd Apr 2024
KING OF PRUSSIA, Pa., April 22, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex”), a leading global provider of indirect tax solutions, today announced that it intends to offer and s
Vertex Provides Preliminary Financial Results for First Quarter 2024 and Announces First Quarter Earnings Call Date
04:17pm, Monday, 22'nd Apr 2024
KING OF PRUSSIA, Pa., April 22, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), a leading global technology provider of indirect tax solutions, today announced preliminary financial results for t
Vertex Pharmaceuticals to Buy Alpine Immune in $4.9B Deal
10:46am, Thursday, 11'th Apr 2024
The acquisition is a bet on a drug under development to treat the kidney condition IgA nephropathy.
Alpine Catapults 37% After Vertex Pledges $4.9 Billion To Buy It
10:36am, Thursday, 11'th Apr 2024
Vertex Pharmaceuticals will pay $4.9 billion to acquire Alpine Immune Sciences. Alpine stock rocketed almost 21% on rumors of the deal.
Vertex may have to pay more than $65 for Alpine Immune stock ($ALPN)
09:23am, Thursday, 11'th Apr 2024
Alpine Immune Sciences Inc (NASDAQ: ALPN) is up 35% on Thursday after Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) said it will acquire the biotechnology company for $65 per share. Is Alpine Imm
Vertex Pharma's $4.9 billion takeover of Alpine Immune expected to boost its rare-disease portfolio
08:06am, Thursday, 11'th Apr 2024
Vertex Pharmaceuticals Inc.'s acquisition of Alpine Immune Sciences Inc. makes strategic sense and will bolster the company's rare-disease franchise, analysts said Thursday.
